The Asia Pacific Virtual Clinical Trials Market would witness market growth of 7.9% CAGR during the forecast period (2020-2026). The growing rate of neurological diseases like tumors, depression, epilepsy, Parkinson’s, and Alzheimer’s combined with the increasing geriatric population are components anticipated to boost the growth of the virtual clinical trial market over the forecast period. Growing clinical trials to find reliable and effective solutions to cure or decline and prevent the spread of neurological disorders and age-related diseases are components that will boost the growth of the virtual clinical trials market during the forecast period.
Furthermore, the instance of tropical and infectious diseases that need new medicines and drugs in numerous countries is a component anticipated to boost the growth of the virtual clinical trial market during the forecast period. Moreover, the modernization of clinical trials to improve productivity and collect information from many sources is a component anticipated to propel the growth of the clinical trial market in the next few years.
Furthermore, the instance of tropical and infectious diseases that need new medicines and drugs in numerous countries is a component anticipated to boost the growth of the virtual clinical trial market during the forecast period. Moreover, the modernization of clinical trials to improve productivity and collect information from many sources is a component anticipated to propel the growth of the clinical trial market in the next few years.
Also, researchers studying cancer confronting major challenges in patient recruitment. Till June 2019, around 14,000 oncology trials were recruited actively with a participation rate of 3% to 8% of possible participants, with a slight number in minority and geriatric populations. Less rate of enrollment presents risks to the effectiveness of particular clinical studies. It may hinder the advancement in treatment and related advantages to results. Therefore, the low rate of recruitment and the requirement for a different population for oncology clinical researches are expected to fuel the acceptance of virtual clinical trials.
Based on Study Type, the market is segmented into Interventional, Observational, and Expanded Access and Others. Based on Indication, the market is segmented into Oncology, Cardiovascular, Immunology, Gastrointestinal, Respiratory, Endocrinology, Ophthalmology and Other Indications. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: Virtual Clinical Trials Market in Asia Pacific is expected to register a CAGR of 7.9% during the forecast period (2020-2026)
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include IQVIA Holdings, Inc., ICON PLC, Laboratory Corporation of America Holdings (Covance, Inc.), Dassault Systemes SE (Medidata Solutions, Inc.), Oracle Corporation, Parexel International Corporation (Pamplona Capital Management), PRA Health Sciences, Inc. (KKR & Co., Inc.), Medpace Holdings, Inc., Medable, Inc. and Clinical Ink, Inc. (G.I. Partners)
By Study Type
By Indication
By Country
Companies Profiled
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 